Efficacy of hormone therapy for osteoporosis in adolescent girls after hematopoietic stem cell transplantation: a longitudinal study

ObjectiveTo assess changes in bone mineral density of adolescent girls diagnosed with hypogonadism after hematopoietic stem cell transplantation (HSCT) during continuous hormone therapy (HT).DesignRetrospective study.SettingDepartment of Obstetrics and Gynecology, Osaka Medical Center and Research Institute for Maternal and Child Health.Patient(s)Twenty-eight adolescent girls with hormone deficiency after HSCT.Intervention(s)All patients were treated with HT.Main Outcome Measure(s)Bone mineral density and markers of bone metabolism were evaluated.Result(s)Twenty-eight patients were enrolled. The girls underwent HSCT at 10.2 ± 4.0 years of age (median ± SD).The first evaluation was performed at 15.1 ± 1.9 years of age, 3.8 ± 3.4 years after HSCT. Bone mineral density increased significantly from −2.7 ± 1.1 (Z-score) to −2.3 ± 1.2 during HT administration for 5.7 ± 2.5 years. Twenty-four of 28 patients (86%) showed a good response to HT. The levels of urinary N-telopeptides of type 1 collagen and serum osteocalcin were high at the first evaluation in 76% and 53% of patients and at the last in 76% and 18%, respectively, thereafter.Conclusion(s)Significant effects on bone metabolism resulting from HSCT were observed; however, HT increased bone mineral density of the hypogonadal patients.